Cumberland FDA Approval for Acetadote Dosing Change

 Thanks mostly to FDA approval of a supplementary New Drug Application (sNDA) for Acetadote (N-acetylcysteine for injection), Cumberland stock has been on a monumental run in December 2024. This approval streamlines the dose schedule, therefore improving safety and efficiency in treating liver damage connected to acetaminophen.

• 
  

Hospitals all around have adopted the simplified strategy to lower medication mistakes and severe non-allergic anaphylactoid responses without sacrificing efficacy. This regulatory landmark has raised investor confidence, which has driven the stock price of the company much higher. Cumberland's development chances are significantly improved by the FDA Orphan Drug and Rare Pediatric Disease Designations for its Duchenne muscular dystrophy medication.

https://finance.yahoo.com/news/cumberland-stock-soars-90-fda-183912684.html